• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma.新辅助放射治疗在胰腺腺癌治疗中的价值
J Clin Oncol. 2021 Dec 1;39(34):3773-3777. doi: 10.1200/JCO.21.01220. Epub 2021 Oct 8.
2
Radiation therapy in the management of pancreatic adenocarcinoma: review of current evidence and future opportunities.放射治疗在胰腺腺癌治疗中的应用：当前证据综述与未来机遇
Chin Clin Oncol. 2017 Jun;6(3):28. doi: 10.21037/cco.2017.06.12.
3
Neoadjuvant stereotactic body radiation therapy for nonmetastatic pancreatic adenocarcinoma.局部立体定向放射治疗新辅助治疗局部晚期不可切除胰腺癌
Acta Oncol. 2019 Sep;58(9):1259-1266. doi: 10.1080/0284186X.2019.1631472. Epub 2019 Jun 25.
4
Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation.接受立体定向体部放疗与常规分割放疗的局部晚期胰腺腺癌患者的治疗结果。
Cancer. 2017 Sep 15;123(18):3486-3493. doi: 10.1002/cncr.30706. Epub 2017 May 10.
5
Perioperative outcomes and survival following neoadjuvant stereotactic body radiation therapy (SBRT) versus intensity-modulated radiation therapy (IMRT) in pancreatic adenocarcinoma.胰腺癌新辅助立体定向体部放射治疗（SBRT）与调强放射治疗（IMRT）后的围手术期结局和生存率
J Surg Oncol. 2018 Apr;117(5):1073-1083. doi: 10.1002/jso.25004. Epub 2018 Feb 15.
6
Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma.局部晚期边缘性或不可切除胰腺癌同期立体定向体放射治疗和奈非那韦的 I 期临床试验。
Radiother Oncol. 2019 Mar;132:55-62. doi: 10.1016/j.radonc.2018.11.002. Epub 2018 Dec 20.
7
Lymphocyte-sparing effect of stereotactic body radiation therapy compared to conventional fractionated radiation therapy in patients with locally advanced pancreatic cancer.立体定向体部放射治疗与常规分割放射治疗局部晚期胰腺癌患者的淋巴细胞保护作用比较。
BMC Cancer. 2019 Oct 22;19(1):977. doi: 10.1186/s12885-019-6220-1.
8
Single- versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity.单剂量与多剂量立体定向体部放射治疗胰腺腺癌：结果和毒性。
Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):918-25. doi: 10.1016/j.ijrobp.2014.06.066. Epub 2014 Oct 18.
9
Radiotherapy for locally advanced pancreatic ductal adenocarcinoma.局部晚期胰腺导管腺癌的放射治疗
Semin Oncol. 2021 Feb;48(1):106-110. doi: 10.1053/j.seminoncol.2021.02.005. Epub 2021 Feb 23.
10
A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma.局部进展期胰腺癌新辅助治疗中应用立体定向体部放疗和术中放疗联合初始化疗的Ⅱ期临床试验方案
BMC Cancer. 2021 Feb 16;21(1):165. doi: 10.1186/s12885-021-07877-7.

引用本文的文献

1
Optimizing neoadjuvant chemoradiation in resectable and borderline resectable pancreatic cancer: Evidence-based insights.优化可切除及边界可切除胰腺癌的新辅助放化疗：基于证据的见解
World J Clin Oncol. 2025 Jul 24;16(7):106107. doi: 10.5306/wjco.v16.i7.106107.
2
Evolving survival patterns in pancreatic adenocarcinoma: a 23-year retrospective observational analysis.胰腺腺癌生存模式的演变：一项23年的回顾性观察分析。
J Gastrointest Oncol. 2025 Jun 30;16(3):1280-1286. doi: 10.21037/jgo-2024-942. Epub 2025 Jun 26.
3
Evolving concepts in adjuvant/neoadjuvant therapy for resectable pancreas cancer.可切除胰腺癌辅助/新辅助治疗的概念演变
J Clin Invest. 2025 Jul 15;135(14). doi: 10.1172/JCI191944.
4
Real-World Evidence of Porto-Mesenteric Vein Resections with Pancreatectomy and the Development of Predictive Clinical Nomograms for Postoperative Outcomes-An Analysis of 389 Cases: The "Porto-Mesenteric Vein Resection-Indian MulticentrE" (PRIME) Study.胰十二指肠切除术联合门静脉-肠系膜上静脉切除的真实世界证据及术后结局预测临床列线图的开发——389例分析：“门静脉-肠系膜上静脉切除-印度多中心”（PRIME）研究
Ann Surg Oncol. 2025 Jul 5. doi: 10.1245/s10434-025-17702-1.
5
Endoscopic Ultrasound-Guided Brachytherapy of Yttrium-90 Implantation Into Pancreas: A Dose-Escalation Pilot Study.内镜超声引导下钇-90植入胰腺近距离放射治疗：剂量递增的初步研究。
MedComm (2020). 2025 Feb 24;6(3):e70117. doi: 10.1002/mco2.70117. eCollection 2025 Mar.
6
Carbohydrate antigen 19-9 (CA19-9) response after induction FOLFIRINOX for locally advanced pancreatic cancer identifies patients who may benefit from surgical exploration: multicentre, observational cohort study.诱导化疗FOLFIRINOX方案治疗局部晚期胰腺癌后碳水化合物抗原19-9（CA19-9）反应可识别可能从手术探查中获益的患者：多中心观察性队列研究
Br J Surg. 2025 Feb 1;112(2). doi: 10.1093/bjs/znaf011.
7
Stereotactic body radiotherapy plus rucosopasem in locally advanced or borderline resectable pancreatic cancer: GRECO-2 phase II study design.立体定向体部放疗联合鲁卡帕尼治疗局部晚期或边界可切除胰腺癌：GRECO-2 期研究设计。
Future Oncol. 2024 Mar;20(8):437-446. doi: 10.2217/fon-2022-1219. Epub 2024 Jan 24.
8
Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer.局部进展期和交界可切除胰腺癌患者的术前化疗、放疗和手术决策。
Nat Rev Gastroenterol Hepatol. 2024 Feb;21(2):101-124. doi: 10.1038/s41575-023-00856-2. Epub 2023 Nov 30.
9
Neoadjuvant therapy for pancreatic cancer.胰腺癌的新辅助治疗。
Nat Rev Clin Oncol. 2023 May;20(5):318-337. doi: 10.1038/s41571-023-00746-1. Epub 2023 Mar 17.
10
Top Pancreatic Tumor Articles from 2021 to Inform Your Cancer Patients.2021 年顶级胰腺肿瘤文章，为您的癌症患者提供信息。
Ann Surg Oncol. 2023 Jun;30(6):3437-3443. doi: 10.1245/s10434-023-13277-x. Epub 2023 Mar 14.

本文引用的文献

1
Radiation Therapy Quality Assurance Analysis of Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Pancreas.联盟 A021501 的放射治疗质量保证分析：术前 mFOLFIRINOX 或 mFOLFIRINOX 联合低分割放射治疗局部可切除胰腺腺癌。
Int J Radiat Oncol Biol Phys. 2024 Sep 1;120(1):111-119. doi: 10.1016/j.ijrobp.2024.03.013. Epub 2024 Mar 15.
2
Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial.在可切除边缘的胰腺癌患者中，即刻手术与短程新辅助吉西他滨联合卡培他滨、FOLFIRINOX或放化疗的比较（ESPAC5）：一项四臂、多中心、随机、2期试验
Lancet Gastroenterol Hepatol. 2023 Feb;8(2):157-168. doi: 10.1016/S2468-1253(22)00348-X. Epub 2022 Dec 12.
3
Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial.立体定向体部放疗联合帕博利珠单抗和曲美替尼与立体定向体部放疗联合吉西他滨治疗手术切除后局部复发性胰腺癌：一项开放标签、随机、对照、2 期临床试验。
Lancet Oncol. 2021 Aug;22(8):1093-1102. doi: 10.1016/S1470-2045(21)00286-2. Epub 2021 Jul 5.
4
Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.胰腺导管腺癌临床实践指南（第 2.2021 版），NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2021 Apr 1;19(4):439-457. doi: 10.6004/jnccn.2021.0017.
5
Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial.可切除胰腺腺癌围手术期化疗的疗效：一项 2 期随机临床试验。
JAMA Oncol. 2021 Mar 1;7(3):421-427. doi: 10.1001/jamaoncol.2020.7328.
6
Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in Combination with High Dose Stereotactic Body Radiation Therapy (SBRT) in Locally Advanced Pancreatic Cancer (PC).GC 4419（一种模拟歧化酶）联合高剂量立体定向体部放疗（SBRT）治疗局部晚期胰腺癌（PC）的随机、双盲、安慰剂对照多中心1-2期适应性试验
Int J Radiat Oncol Biol Phys. 2020 Dec 1;108(5):1399-1400. doi: 10.1016/j.ijrobp.2020.09.022. Epub 2020 Nov 18.
7
Impact of neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT) on R0 resection rate for borderline resectable and locally advanced pancreatic cancer.新辅助化疗和立体定向体部放疗（SBRT）对临界可切除和局部晚期胰腺癌R0切除率的影响。
HPB (Oxford). 2021 Jul;23(7):1072-1083. doi: 10.1016/j.hpb.2020.11.004. Epub 2020 Dec 1.
8
A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours.在晚期实体瘤患者中进行的 DNA 依赖性蛋白激酶抑制剂 peposertib（前称 M3814）的首次人体 1 期研究。
Br J Cancer. 2021 Feb;124(4):728-735. doi: 10.1038/s41416-020-01151-6. Epub 2020 Nov 24.
9
Patterns of Failure After Neoadjuvant Stereotactic Body Radiation Therapy or Fractionated Chemoradiation in Resectable and Borderline Resectable Pancreatic Cancer.可切除和交界可切除胰腺癌新辅助立体定向体放射治疗或分割放化疗后失败模式。
Pancreas. 2020 Aug;49(7):941-946. doi: 10.1097/MPA.0000000000001602.
10
Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial.可切除及临界可切除胰腺癌的术前放化疗与直接手术对比：荷兰随机III期PREOPANC试验结果
J Clin Oncol. 2020 Jun 1;38(16):1763-1773. doi: 10.1200/JCO.19.02274. Epub 2020 Feb 27.

Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma.

作者信息

Hall William A, Dawson Laura A, Hong Theodore S, Palta Manisha, Herman Joseph M, Evans Douglas B, Tsai Susan, Ferrone Cristina R, B Fleming Jason, Chang Daniel T, Crane Christopher, Koong Albert C, Oar Andrew, Parikh Parag, Erickson Beth, Hoffe Sarah, Goodman Karyn A

机构信息

Medical College of Wisconsin, Department of Radiation Oncology and the LaBahn Pancreatic Cancer Program, Milwaukee, WI.

Medical College of Wisconsin, Department of Surgery and the LaBahn Pancreatic Cancer Program, Milwaukee, WI.

出版信息

J Clin Oncol. 2021 Dec 1;39(34):3773-3777. doi: 10.1200/JCO.21.01220. Epub 2021 Oct 8.

DOI:10.1200/JCO.21.01220
PMID:34623894
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8608256/
Abstract
摘要